Scholarlink

<p>The treatment of Alzheimer’s disease (AD) is currently limited to symptomatic therapy with acetylcholinesterase inhibitors and memantine, which contribute to temporary improvements in cognitive functions and increased independence in everyday life but have little effect on the rate of progression of the neurodegenerative process. The objective of this review is to analyze contemporary studies of pathogenetic (disease-modifying therapy) of AD. Modern concepts hold that the pathogenesis of AD is associated with the accumulation of amyloid protein, hyperphosphorylation of tau protein, neuroinflammation, mitochondrial dysfunction, etc. The most promising means of pathogenetic therapy are currently believed to be anti-amyloid antibodies, drugs for anti-tau therapy, and antidiabetic and anti-inflammatory therapy. Drugs for anti-amyloid therapy, such as aducunumab, lecanumab, and donanemab, have recently been officially approved for practical application in some countries. Therapeutic strategies for influencing tau protein pathology, neuroinflammation, insulin resistance, and other mechanisms of neurodegeneration are also under active study. Along with drug therapy, non-invasive brain stimulation methods such as transcranial magnetic stimulation and transcranial electrical stimulation are being actively developed; these have a high safety profile and demonstrated efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prospects for the Treatment of Alzheimer’s Disease

  • 期刊论文

  • 发表日期：

    2025年9月11日

查看全文
  • N. V. Vakhnina,
  • D. K. Novikov,
  • K. A. Vekhova,
  • A. M. Zhuk,
  • D. L. Klimanovich,
  • A. I. Isaikin,
  • V. V. Zakharov

摘要

The treatment of Alzheimer’s disease (AD) is currently limited to symptomatic therapy with acetylcholinesterase inhibitors and memantine, which contribute to temporary improvements in cognitive functions and increased independence in everyday life but have little effect on the rate of progression of the neurodegenerative process. The objective of this review is to analyze contemporary studies of pathogenetic (disease-modifying therapy) of AD. Modern concepts hold that the pathogenesis of AD is associated with the accumulation of amyloid protein, hyperphosphorylation of tau protein, neuroinflammation, mitochondrial dysfunction, etc. The most promising means of pathogenetic therapy are currently believed to be anti-amyloid antibodies, drugs for anti-tau therapy, and antidiabetic and anti-inflammatory therapy. Drugs for anti-amyloid therapy, such as aducunumab, lecanumab, and donanemab, have recently been officially approved for practical application in some countries. Therapeutic strategies for influencing tau protein pathology, neuroinflammation, insulin resistance, and other mechanisms of neurodegeneration are also under active study. Along with drug therapy, non-invasive brain stimulation methods such as transcranial magnetic stimulation and transcranial electrical stimulation are being actively developed; these have a high safety profile and demonstrated efficacy.